These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30237518)

  • 1. Structural basis for recognition of the malaria vaccine candidate Pfs48/45 by a transmission blocking antibody.
    Lennartz F; Brod F; Dabbs R; Miura K; Mekhaiel D; Marini A; Jore MM; Søgaard MM; Jørgensen T; de Jongh WA; Sauerwein RW; Long CA; Biswas S; Higgins MK
    Nat Commun; 2018 Sep; 9(1):3822. PubMed ID: 30237518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced immunogenicity of Plasmodium falciparum gamete surface antigen (Pfs48/45) in mice after disruption of disulphide bonds - evaluating effect of interferon-γ-inducible lysosomal thiol reductase.
    Merino KM; Bansal GP; Kumar N
    Immunology; 2016 Aug; 148(4):433-47. PubMed ID: 27177843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies.
    Ko KT; Lennartz F; Mekhaiel D; Guloglu B; Marini A; Deuker DJ; Long CA; Jore MM; Miura K; Biswas S; Higgins MK
    Nat Commun; 2022 Sep; 13(1):5603. PubMed ID: 36153317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45.
    Kundu P; Semesi A; Jore MM; Morin MJ; Price VL; Liang A; Li J; Miura K; Sauerwein RW; King CR; Julien JP
    Nat Commun; 2018 Oct; 9(1):4458. PubMed ID: 30367064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Plant-Produced in vivo deglycosylated full-length Pfs48/45 as a Transmission-Blocking Vaccine Candidate against malaria.
    Mamedov T; Cicek K; Miura K; Gulec B; Akinci E; Mammadova G; Hasanova G
    Sci Rep; 2019 Jul; 9(1):9868. PubMed ID: 31285498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli.
    Chowdhury DR; Angov E; Kariuki T; Kumar N
    PLoS One; 2009 Jul; 4(7):e6352. PubMed ID: 19623257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.
    Theisen M; Jore MM; Sauerwein R
    Expert Rev Vaccines; 2017 Apr; 16(4):329-336. PubMed ID: 28043178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.
    Datta D; Bansal GP; Gerloff DL; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2017 Jan; 35(2):264-272. PubMed ID: 27912985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice.
    Outchkourov NS; Roeffen W; Kaan A; Jansen J; Luty A; Schuiffel D; van Gemert GJ; van de Vegte-Bolmer M; Sauerwein RW; Stunnenberg HG
    Proc Natl Acad Sci U S A; 2008 Mar; 105(11):4301-5. PubMed ID: 18332422
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Singh SK; Thrane S; Chourasia BK; Teelen K; Graumans W; Stoter R; van Gemert GJ; van de Vegte-Bolmer MG; Nielsen MA; Salanti A; Sander AF; Sauerwein RW; Jore MM; Theisen M
    Front Immunol; 2019; 10():1256. PubMed ID: 31231386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterologous expression of the C-terminal antigenic domain of the malaria vaccine candidate Pfs48/45 in the green algae Chlamydomonas reinhardtii.
    Jones CS; Luong T; Hannon M; Tran M; Gregory JA; Shen Z; Briggs SP; Mayfield SP
    Appl Microbiol Biotechnol; 2013 Mar; 97(5):1987-95. PubMed ID: 22592550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins.
    Singh K; Burkhardt M; Nakuchima S; Herrera R; Muratova O; Gittis AG; Kelnhofer E; Reiter K; Smelkinson M; Veltri D; Swihart BJ; Shimp R; Nguyen V; Zhang B; MacDonald NJ; Duffy PE; Garboczi DN; Narum DL
    Commun Biol; 2020 Jul; 3(1):395. PubMed ID: 32709983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epitope analysis of the malaria surface antigen pfs48/45 identifies a subdomain that elicits transmission blocking antibodies.
    Outchkourov N; Vermunt A; Jansen J; Kaan A; Roeffen W; Teelen K; Lasonder E; Braks A; van de Vegte-Bolmer M; Qiu LY; Sauerwein R; Stunnenberg HG
    J Biol Chem; 2007 Jun; 282(23):17148-56. PubMed ID: 17426022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
    Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques.
    Datta D; Bansal GP; Grasperge B; Martin DS; Philipp M; Gerloff D; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2017 Dec; 35(50):7049-7056. PubMed ID: 29132995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly potent, naturally acquired human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to mosquitoes.
    Fabra-García A; Hailemariam S; de Jong RM; Janssen K; Teelen K; van de Vegte-Bolmer M; van Gemert GJ; Ivanochko D; Semesi A; McLeod B; Vos MW; de Bruijni MHC; Bolscher JM; Szabat M; Vogt S; Kraft L; Duncan S; Kamya MR; Feeney ME; Jagannathan P; Greenhouse B; Dechering KJ; Sauerwein RW; King CR; MacGill RS; Bousema T; Julien JP; Jore MM
    Immunity; 2023 Feb; 56(2):406-419.e7. PubMed ID: 36792574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based
    Singh SK; Plieskatt J; Chourasia BK; Fabra-García A; Garcia-Senosiain A; Singh V; Bengtsson KL; Reimer JM; Sauerwein R; Jore MM; Theisen M
    Front Immunol; 2020; 11():606266. PubMed ID: 33505395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.
    Mistarz UH; Singh SK; Nguyen TTTN; Roeffen W; Yang F; Lissau C; Madsen SM; Vrang A; Tiendrebeogo RW; Kana IH; Sauerwein RW; Theisen M; Rand KD
    Pharm Res; 2017 Sep; 34(9):1970-1983. PubMed ID: 28646324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses.
    McLeod B; Mabrouk MT; Miura K; Ravichandran R; Kephart S; Hailemariam S; Pham TP; Semesi A; Kucharska I; Kundu P; Huang WC; Johnson M; Blackstone A; Pettie D; Murphy M; Kraft JC; Leaf EM; Jiao Y; van de Vegte-Bolmer M; van Gemert GJ; Ramjith J; King CR; MacGill RS; Wu Y; Lee KK; Jore MM; King NP; Lovell JF; Julien JP
    Immunity; 2022 Sep; 55(9):1680-1692.e8. PubMed ID: 35977542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of full-length Plasmodium falciparum P48/45 in P. berghei blood stages: A method to express and evaluate vaccine antigens.
    Othman AS; Lin JW; Franke-Fayard BM; Kroeze H; van Pul FJA; Chevalley-Maurel S; Ramesar J; Marin-Mogollon C; Jore MM; Morin MJ; Long CA; Sauerwein R; Birkett A; Miura K; Janse CJ; Khan SM
    Mol Biochem Parasitol; 2018 Sep; 224():44-49. PubMed ID: 30053393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.